Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597146937> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2597146937 endingPage "610" @default.
- W2597146937 startingPage "610" @default.
- W2597146937 abstract "610 Background: Biologics, such as trastuzumab, are an important part of oncology treatment paradigms, although access to such therapies is a challenge in emerging markets and in certain areas of more developed countries such as the United States (US). Biosimilars have the potential to increase access to biologic therapies by offering a comparable but more affordable alternative relative to the innovator biologic. This study examined access to trastuzumab and identified barriers to its use in HER2+ breast cancer patients in the US, Mexico (MEX), Turkey (TUR), Russia (RUS), and Brazil (BRZ). The study also examined whether availability of a biosimilar to trastuzumab would improve access to, and use of, HER2 monoclonal antibody therapy. Methods: Medical oncologists (N=500) completed a blinded survey examining their use of trastuzumab. Results: Across all countries, oncologists reported “not so often”, “rarely”, or “never” using trastuzumab in a neoadjuvant (27%), adjuvant (8%), or metastatic (8%) setting. Common barriers to the use of trastuzumab were related to insurance coverage, drug availability, cost to the patient, treatment guidelines, and patient comorbidities. Oncologists also reported having had to cancel or delay treatment with trastuzumab due to reimbursement issues (Overall=31%, US=10%, BRZ=48%, MEX=37%, TUR=16%, RUS=76%). Overall, 45% of oncologists reported that they would increase the use of HER2 monoclonal antibody therapy if a lower cost biosimilar to trastuzumab was available, including 29% of US oncologists. This percentage was higher in BRZ (53%), MEX (63%), and RUS (81%). Oncologists reported that use would increase across all treatment settings. Conclusions: The availability of a trastuzumab biosimilar may increase use of HER2 monoclonal antibody therapy in the breast cancer arena across all treatment settings in the US and, to an even greater extent, in the emerging markets of RUS, MEX, and BRZ. A biosimilar could provide benefit to patients who currently do not receive trastuzumab, or receive less than optimal treatment, due to insurance coverage or cost issues related to such treatment. Sponsored by Pfizer Inc." @default.
- W2597146937 created "2017-03-23" @default.
- W2597146937 creator A5000459628 @default.
- W2597146937 creator A5003897511 @default.
- W2597146937 creator A5018551530 @default.
- W2597146937 creator A5077630534 @default.
- W2597146937 date "2014-05-20" @default.
- W2597146937 modified "2023-09-27" @default.
- W2597146937 title "Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the United States and emerging markets." @default.
- W2597146937 doi "https://doi.org/10.1200/jco.2014.32.15_suppl.610" @default.
- W2597146937 hasPublicationYear "2014" @default.
- W2597146937 type Work @default.
- W2597146937 sameAs 2597146937 @default.
- W2597146937 citedByCount "0" @default.
- W2597146937 crossrefType "journal-article" @default.
- W2597146937 hasAuthorship W2597146937A5000459628 @default.
- W2597146937 hasAuthorship W2597146937A5003897511 @default.
- W2597146937 hasAuthorship W2597146937A5018551530 @default.
- W2597146937 hasAuthorship W2597146937A5077630534 @default.
- W2597146937 hasBestOaLocation W25971469372 @default.
- W2597146937 hasConcept C111919701 @default.
- W2597146937 hasConcept C121608353 @default.
- W2597146937 hasConcept C126322002 @default.
- W2597146937 hasConcept C143998085 @default.
- W2597146937 hasConcept C160735492 @default.
- W2597146937 hasConcept C162324750 @default.
- W2597146937 hasConcept C177713679 @default.
- W2597146937 hasConcept C2776473838 @default.
- W2597146937 hasConcept C2777589142 @default.
- W2597146937 hasConcept C2777863537 @default.
- W2597146937 hasConcept C2779134260 @default.
- W2597146937 hasConcept C2779703844 @default.
- W2597146937 hasConcept C2779786085 @default.
- W2597146937 hasConcept C2911221801 @default.
- W2597146937 hasConcept C34974158 @default.
- W2597146937 hasConcept C41008148 @default.
- W2597146937 hasConcept C50522688 @default.
- W2597146937 hasConcept C512399662 @default.
- W2597146937 hasConcept C530470458 @default.
- W2597146937 hasConcept C59491497 @default.
- W2597146937 hasConcept C60644358 @default.
- W2597146937 hasConcept C71924100 @default.
- W2597146937 hasConcept C86803240 @default.
- W2597146937 hasConceptScore W2597146937C111919701 @default.
- W2597146937 hasConceptScore W2597146937C121608353 @default.
- W2597146937 hasConceptScore W2597146937C126322002 @default.
- W2597146937 hasConceptScore W2597146937C143998085 @default.
- W2597146937 hasConceptScore W2597146937C160735492 @default.
- W2597146937 hasConceptScore W2597146937C162324750 @default.
- W2597146937 hasConceptScore W2597146937C177713679 @default.
- W2597146937 hasConceptScore W2597146937C2776473838 @default.
- W2597146937 hasConceptScore W2597146937C2777589142 @default.
- W2597146937 hasConceptScore W2597146937C2777863537 @default.
- W2597146937 hasConceptScore W2597146937C2779134260 @default.
- W2597146937 hasConceptScore W2597146937C2779703844 @default.
- W2597146937 hasConceptScore W2597146937C2779786085 @default.
- W2597146937 hasConceptScore W2597146937C2911221801 @default.
- W2597146937 hasConceptScore W2597146937C34974158 @default.
- W2597146937 hasConceptScore W2597146937C41008148 @default.
- W2597146937 hasConceptScore W2597146937C50522688 @default.
- W2597146937 hasConceptScore W2597146937C512399662 @default.
- W2597146937 hasConceptScore W2597146937C530470458 @default.
- W2597146937 hasConceptScore W2597146937C59491497 @default.
- W2597146937 hasConceptScore W2597146937C60644358 @default.
- W2597146937 hasConceptScore W2597146937C71924100 @default.
- W2597146937 hasConceptScore W2597146937C86803240 @default.
- W2597146937 hasIssue "15_suppl" @default.
- W2597146937 hasLocation W25971469371 @default.
- W2597146937 hasLocation W25971469372 @default.
- W2597146937 hasOpenAccess W2597146937 @default.
- W2597146937 hasPrimaryLocation W25971469371 @default.
- W2597146937 hasRelatedWork W1985202864 @default.
- W2597146937 hasRelatedWork W2597146937 @default.
- W2597146937 hasRelatedWork W2761356983 @default.
- W2597146937 hasRelatedWork W2934222321 @default.
- W2597146937 hasRelatedWork W3095573000 @default.
- W2597146937 hasRelatedWork W3202363710 @default.
- W2597146937 hasRelatedWork W4283519219 @default.
- W2597146937 hasRelatedWork W4292478226 @default.
- W2597146937 hasRelatedWork W4294226044 @default.
- W2597146937 hasRelatedWork W4310753276 @default.
- W2597146937 hasVolume "32" @default.
- W2597146937 isParatext "false" @default.
- W2597146937 isRetracted "false" @default.
- W2597146937 magId "2597146937" @default.
- W2597146937 workType "article" @default.